EUVIMEDEUVIMED entdecken
Crossref

Gabapentinoid dosing and adverse events in patients with chronic kidney disease

Drew A Wells, Kayla Washington, Brandon Cave, Rongshun Zhu, Joanna Q Hudson

Clinical Nephrology · 01.09.2022 · 98 (3) · 147-154

DOI: 10.5414/cn110815 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Nephrology, erschienen am 01.09.2022. Verfasst von Drew A Wells und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Antipsychotic Agents, Kidney Failure, Chronic, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 6-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsKidney Failure, ChronicRenal Insufficiency, ChronicAdultAgedFemaleGabapentinHumansMaleMiddle AgedRetrospective Studies

Substanzen

Antipsychotic AgentsGabapentin

Zitieren

APA

Wells, D. A., Washington, K., Cave, B., Zhu, R., & Hudson, J. Q. (2022). Gabapentinoid dosing and adverse events in patients with chronic kidney disease. Clinical Nephrology, 98(3), 147-154. https://doi.org/10.5414/cn110815

Vancouver

Wells DA, Washington K, Cave B, Zhu R, Hudson JQ. Gabapentinoid dosing and adverse events in patients with chronic kidney disease. Clinical Nephrology. 2022;98(3):147-154. doi:10.5414/cn110815

BibTeX
@article{Wells2022,
  author = {Wells, Drew A and Washington, Kayla and Cave, Brandon and Zhu, Rongshun and Hudson, Joanna Q},
  title = {Gabapentinoid dosing and adverse events in patients with chronic kidney disease},
  journal = {Clinical Nephrology},
  year = {2022},
  volume = {98},
  number = {3},
  pages = {147--154},
  doi = {10.5414/cn110815}
}
Kostenlos starten →